Childhood Liver Disease Research and Education Network Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2014
NCT02057692
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

maralixibat (LIVMARLI) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alagille Syndrome (Phase 2)

Liver Diseases (Phase 2)

Pruritus (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1